Weight Loss Injections for Men UK: What Works, Costs & How to Start

Men and women lose weight differently, and this has implications for how GLP-1 medications like Ozempic (semaglutide) and Mounjaro (tirzepatide) perform in practice.

Physiological differences in male obesity: - Men tend to accumulate more visceral fat (abdominal, around organs) rather than subcutaneous fat - Visceral fat is metabolically more active and more responsive to both caloric restriction and GLP-1 agonists - Men typically have higher baseline metabolic rates due to greater lean muscle mass, meaning caloric expenditure during treatment is higher - Male sex hormones, particularly testosterone, influence fat distribution, appetite regulation and insulin sensitivity

What this means for weight loss outcomes: - Men generally lose weight faster in the early stages of GLP-1 treatment, partly due to higher metabolic rate - The visceral fat reduction achievable with semaglutide and tirzepatide is particularly beneficial for men, given the cardiovascular risk associated with central obesity - However, men may experience somewhat lower percentage total body weight loss compared to women in some trial analyses — the mechanism is not fully understood but may relate to differences in appetite signalling

Trial data for men: - In the STEP and SURPASS trials, men achieved clinically significant weight loss across all doses - Cardiovascular benefit from visceral fat reduction was pronounced in male subgroup analyses

*This article is for educational purposes only and does not constitute medical advice. Always consult a qualified prescriber before starting any injectable medication.*

All GLP-1 receptor agonists available in the UK are effective for weight management in men, but there are practical differences worth understanding.

Semaglutide (Wegovy/Ozempic): - Well-established evidence base; extensive real-world data in both diabetes and obesity settings - Ozempic licensed for Type 2 diabetes; Wegovy licensed for weight management (BMI ≥30 with comorbidity, or ≥35 without) - Once-weekly injection; pre-filled autoinjector pen - Mean weight loss in men in trials: approximately 12–15% body weight at 2.4mg dose

Tirzepatide (Mounjaro): - Dual GIP/GLP-1 mechanism provides superior weight loss in head-to-head comparisons - SURMOUNT-1 trial showed mean weight loss of 20.9% at 15mg dose — men in this trial achieved losses consistent with the overall population - Greater appetite suppression and improved insulin sensitivity may be particularly relevant for men with significant visceral fat and insulin resistance - Increasingly regarded as the first-choice pharmacological option for weight management where access allows

Liraglutide (Saxenda): - Daily injection; older GLP-1 agonist with established safety profile - Mean weight loss approximately 8% — less than semaglutide or tirzepatide - May be preferred in patients who have failed semaglutide and need a different titration schedule

AOD-9604 — research context: - A fragment of human growth hormone sometimes discussed in weight management circles - No licensed indication in the UK; no large-scale human trial data - Should not be compared with licensed GLP-1 medications for clinical decision-making

One area of particular interest for men is the relationship between weight loss, GLP-1 therapy and testosterone levels.

Obesity and testosterone: - Obesity is strongly associated with lower total and free testosterone in men — a relationship that is bidirectional (low testosterone promotes fat gain; excess fat aromatises testosterone to oestrogen) - Visceral adipose tissue is particularly active in converting testosterone to oestradiol via aromatase enzyme activity - Many obese men have clinically low testosterone (hypogonadism) without a primary testicular or pituitary cause — this is sometimes called obesity-related hypogonadism

Effect of GLP-1-mediated weight loss on testosterone: - Studies consistently show that significant weight loss (regardless of method) is associated with meaningful increases in testosterone in men with obesity - A published analysis of SUSTAIN trial data found semaglutide-treated men had measurable improvements in testosterone levels proportional to weight lost - This has clinical relevance: men may notice improvements in energy, mood, libido and erectile function as a secondary benefit of successful weight management

Should men on GLP-1 therapy check testosterone? - If you have symptoms of low testosterone (fatigue, low libido, erectile dysfunction, depression), a baseline testosterone test is appropriate — discuss with your GP - GLP-1 therapy is not a substitute for TRT (testosterone replacement therapy) in men with clinically confirmed hypogonadism, but weight loss may allow some men to avoid or discontinue TRT as testosterone normalises - Inform your prescriber if you are already on TRT before starting GLP-1 medication

Many men are interested in preserving or building muscle during weight loss — a goal that requires different monitoring to simply tracking scale weight.

The body composition challenge on GLP-1 therapy: - GLP-1 agonists produce weight loss primarily through caloric restriction (reduced appetite) — without adequate protein intake and resistance exercise, a proportion of the weight lost may be lean muscle mass - Studies suggest approximately 25–40% of weight lost on semaglutide may be lean mass — comparable to other caloric restriction approaches - For men who are physically active or interested in body composition, this is an important consideration

Strategies for preserving muscle mass during GLP-1 treatment: - Protein intake: Aim for 1.6–2.2g protein per kg of target body weight daily — adequate protein supports muscle protein synthesis during caloric deficit - Resistance training: Regular resistance exercise is the strongest evidence-based intervention for preserving lean mass during weight loss - Avoid aggressive caloric restriction: GLP-1 medications can suppress appetite to the point where caloric intake drops very low — eating too little accelerates muscle catabolism

What to measure beyond weight: - DEXA scan: Gold standard for body composition (fat mass vs lean mass); available privately at some UK clinics for approximately £100–£200 - Waist circumference: Correlates well with visceral fat reduction — target below 94cm for men - Strength metrics: Tracking gym performance (lifts, endurance) provides a practical indicator of whether lean mass is being maintained

Discuss body composition goals with your prescriber — they can refer to a dietitian or exercise physiologist for tailored guidance.

Access to weight loss injections for men follows the same NHS criteria as for women, but there are a few practical points worth noting.

NHS access: - Wegovy is commissioned via NHS Tier 3 weight management services — referral typically from GP - Eligibility requires BMI ≥35 with comorbidity or ≥30 in high-risk groups; Mounjaro weight management licence is under active NHS commissioning as of 2025/26 - Men with Type 2 diabetes have a clearer NHS route via diabetes prescribing (Ozempic, Mounjaro for T2D) - Waiting times for Tier 3 services are long in many NHS areas; GP referral and patience are required

Private access: - Private weight management clinics (telehealth and in-person) offer the fastest route to treatment for most men - Reputable providers include CQC-registered services with GMC-licensed prescribers - Cost range: £150–£300/month for medication; £50–£200 for consultations - Ensure the clinic offers ongoing monitoring (blood pressure, blood tests at appropriate intervals) and not just medication supply

Red flags when choosing a provider: - No face-to-face or video consultation required before prescribing - No medical history review or contraindication screening - Inability to contact a prescriber if side effects occur - Prices that seem significantly below market rate for genuine licensed medication

Starting treatment: - Book a consultation (GP or private clinic); bring a list of current medications and your most recent weight/BMI - Discuss your specific goals: scale weight, body composition, cardiovascular risk, or diabetes management — this influences which medication and monitoring approach is recommended

*This article is for educational purposes only. Always consult a qualified medical prescriber before starting injectable weight management medication.*